Answer
Sandostatin (octreotide acetate) is indicated for symptom control and reduction of GH and IGF-1 levels in patients with acromegaly inadequately controlled by surgery or radiotherapy, those unfit or unwilling to undergo surgery, or those awaiting radiotherapy’s full effect.
Sources for this answer
- Sandostatin 50, 100, 500 microgram/1 ml solution for injection/infusionNovartis Pharmaceuticals UK Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 27Document updated
Sources checked